Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the second quarter ended June 30, 2013 and other business updates.
Total product revenue was $235.4 million for the second quarter of 2013, a 30% increase compared to $181.0 million for the second quarter of 2012. Total product revenue for the first six months of 2013 was $438.0 million, a 24% increase compared to $352.1 million for the first six months of 2012. XIFAXAN® revenue for the second quarter of 2013 was $150.6 million, a 29% increase compared to $116.7 million for the second quarter of 2012.
Hey, check out all the engineering jobs. Post your resume today!
